Northwest Biotherapeutics, Inc  

(Public, NASDAQ:NWBO)   Watch this stock  
-0.15 (-2.99%)
Real-time:   10:31AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.81 - 5.05
52 week 3.10 - 10.64
Open 5.03
Vol / Avg. 128,316.00/428,401.00
Mkt cap 290.35M
P/E     -
Div/yield     -
EPS -2.40
Shares 59.50M
Beta 2.98
Inst. own 26%
Sep 9, 2014
Northwest Biotherapeutics Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -8132.14%
Operating margin - -6856.98%
EBITD margin - -6855.50%
Return on average assets -827.04% -499.27%
Return on average equity - -
Employees 9 -
CDP Score - -


Suite 800, 4800 Montgomery Lane
United States - Map
+1-240-4979024 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Northwest Biotherapeutics, Inc. is a development-stage company. The Company focuses on discovering, developing, and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. The Company's approach in developing cancer therapies utilizes its capability in the biology of dendritic cells (DC), which are a type of white blood cells that activate the immune system. It focused on advancing a dendritic cell immunotherapy for prostate and brain cancer. The Company has two basic technology platforms applicable to cancer therapeutics: dendritic cell-based cancer vaccines, which it calls DCVax, and monoclonal antibodies for cancer therapeutics. Its DCVax dendritic cell-based cancer vaccine program is its main technology platform.

Officers and directors

Linda F. Powers Chairperson of the Board, President, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Leslie J. Goldman Senior Vice President - Business Development
Age: 69
Bio & Compensation  - Reuters
Anthony E. Maida Ph.D. Senior Vice President - Clinical Research
Age: 61
Bio & Compensation  - Reuters
Marnix L. Bosch Ph.D Chief Technical Officer
Age: 54
Bio & Compensation  - Reuters
Alton L. Boynton Ph.D. Chief Scientific Officer, Director
Age: 70
Bio & Compensation  - Reuters
Robert A. Farmer Independent Director
Age: 74
Bio & Compensation  - Reuters
Jerry J. Jasinowski Independent Director
Age: 71
Bio & Compensation  - Reuters
Navid Malik Independent Director
Age: 45
Bio & Compensation  - Reuters